Vancomycin: We Can't Get There From Here

• Published in: Clinical infectious diseases Vol. 52; no. 8; pp. 969 - 974
• Main Authors: Patel, Nimish, Pai, Manjunath P., Rodvold, Keith A., Lomaestro, Ben, Drusano, George L., Lodise, Thomas P.
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 15.04.2011
• Subjects: Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - pharmacokinetics; Anti-Bacterial Agents - pharmacology; Antibacterial agents; Antibiotics; Antibiotics. Antiinfectious agents. Antiparasitic agents; ARTICLES AND COMMENTARIES; Biological and medical sciences; Dosage; Dose response relationship; Effectiveness studies; Humans; Infections; Infectious diseases; Kidneys; Medical sciences; Methicillin-Resistant Staphylococcus aureus - drug effects; Microbial Sensitivity Tests; Monte Carlo methods; Nephrotoxicity; Pharmacology; Pharmacology. Drug treatments; Population estimates; Ratios; Regression analysis; Serum - chemistry; Simulation; Staphylococcal Infections - drug therapy; Staphylococcal Infections - microbiology; Staphylococcus aureus; Staphylococcus infections; Toxicity; Vancomycin - administration & dosage; Vancomycin - adverse effects; Vancomycin - pharmacokinetics; Vancomycin - pharmacology; Infection; Antibiotic; Peptides; Glycopeptide; Polypeptide; Vancomycin; Antibacterial agent

Background. We sought to characterize the pharmacodynamic profile of the more intensive vancomycin dosing regimens currently used in response to the recent vancomycin guidelines. Methods. A series of Monte Carlo simulations was performed for vancomycin regimens ranging from .5 g intravenous (IV) Q12...